Metabolic targets for cancer therapy

641 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression (2015, background): “Besides glycolytic rate-limiting enzymes, glucose transporters and other metabolic enzymes have also been selected as targets for drug screening [151].”
Autophagy in malignant transformation and cancer progression (2015, positive): “…and antioxidant defenses, (2) mitochondrial respiration remains high to satisfy increased energy demands; and (3) several amino acids, including glutamine and serine, become essential as a means to cope with exacerbated metabolic functions (Hanahan & Weinberg, 2011; Galluzzi et al , 2013).”
Mitochondrial metabolism and cancer (2017, background): “One of the main problems with targeting mitochondria as a strategy to kill malignant cells or sensitize them to treatment is that multiple immune effector cells, and in particular CD8 cytotoxic T lymphocytes (CTLs, which are involved in the efficacy of many – if not all – therapies), display remarka”
Targeting Metabolism for Cancer Therapy (2017, background): “…the aberrant metabolism of proliferating cancer cells presents potential opportunities, and there has been a growing interest in studying how best to target cancer metabolism (Bobrovnikova-Marjon and Hurov, 2014; Galluzzi et al., 2013; MartinezOutschoorn et al., 2017; Vander Heiden, 2011).”
Metabolic control of cell death (2014, background): “bisphosphatase) favors PMK2 inactivation (5).”